US20070003116A1 - Method and system for atherosclerosis risk scoring - Google Patents
Method and system for atherosclerosis risk scoring Download PDFInfo
- Publication number
- US20070003116A1 US20070003116A1 US11/172,415 US17241505A US2007003116A1 US 20070003116 A1 US20070003116 A1 US 20070003116A1 US 17241505 A US17241505 A US 17241505A US 2007003116 A1 US2007003116 A1 US 2007003116A1
- Authority
- US
- United States
- Prior art keywords
- fibrous cap
- region
- status
- artery
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0012—Biomedical image inspection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/50—Clinical applications
- A61B6/504—Clinical applications involving diagnosis of blood vessels, e.g. by angiography
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H30/00—ICT specially adapted for the handling or processing of medical images
- G16H30/40—ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
- A61B8/0833—Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30101—Blood vessel; Artery; Vein; Vascular
Definitions
- the present invention relates generally to methods for assessing a patient's risk associated with atherosclerosis and, more particularly, to clinically efficient methods for characterizing such risks.
- Cardiovascular disease secondary to atherosclerosis is the leading cause of mortality and morbidity worldwide. Growing evidence suggests that the decisive factor determining increased risk for atherosclerotic plaque to cause clinical events is plaque composition rather than the degree of luminal narrowing as measured by angiography.
- Atherosclerosis is a form of arteriosclerosis that is characterized by the deposition of plaques containing cholesterol and lipids on the innermost layer of the walls of arteries.
- Atherosclerosis is currently understood to be a chronic inflammatory disease rather than an inevitable degenerative aging process. The condition usually affects large- and medium-sized arteries.
- plaque deposits can significantly reduce the blood's flow through an artery, the more serious risk is generally associated with the instigation of an acute clinical event through plaque rupture and thrombosis. In particular, serious damage can occur if an arterial plaque deposit becomes fragile and ruptures, fissures, or ulcerates.
- Plaque rupture, fissure, or ulcer can cause blood clots to form that block or occlude blood flow and/or break off and travel to other parts of the body. If such blood clots block a blood vessel that feeds the heart, it causes a heart attack. If the blood clot blocks a blood vessel that feeds the brain, it causes a stroke. Similarly, if blood supply to the arms or legs is reduced, it can cause difficulty in walking or light exercise and other collateral damage. Recent studies indicate that thrombotic complications of atherosclerosis remain the leading cause of morbidity and mortality in Western society.
- Atherosclerosis may start in childhood and may progress at varying rates as a person ages. In some people, atherosclerosis progresses rapidly, even at a relatively young age. Tobacco smoke greatly worsens atherosclerosis and speeds its growth in the coronary arteries, the aorta, and arteries in the legs. Although some factors that correlate with a higher risk of atherosclerosis are not controllable, such as gender and family history, other correlated risk factors are controllable—including, for example, high blood cholesterol levels, exposure to tobacco smoke, high blood pressure, obesity, and physical inactivity.
- MRI magnetic resonance imaging
- CT computed tomography
- X-ray angiography ultrasound.
- Prior art methods for assessing an individual's risk of a clinically significant event such as a stroke or heart attack related to atherosclerotic deposits in an individual's arteries have primarily been directed to evaluating the effect that the plaque deposit has on the blood flow through the artery.
- the risk associated with rupture, fissure, or ulceration of plaque may be present even when the plaque deposit does not significantly reduce the flow of blood in an artery.
- arteries and other blood vessels will sometimes expand or “remodel” in the region of a significant atherosclerotic plaque deposit such that the lumen area does not decrease sufficiently to significantly reduce blood flow. If the plaque ruptures, it may nevertheless create a blood clot that may travel to a critical area to cause a clinical event.
- the susceptibility of a plaque deposit to structural failure is difficult to determine.
- a simplified scoring system that takes into account a large amount of data and a number of different factors in a simplified manner to rapidly characterize the patient's risk.
- Such methods can provide a rapid means for evaluating a patient's condition and the urgency of providing appropriate treatments.
- a well known example of such a scoring system is the Apgar scale ubiquitously used to rapidly judge the health of a new born baby wherein, at one minute and again at five minutes after birth, the infant is evaluated for heart rate, respiration, muscle tone, reflex response, and skin color. Each factor is given a score between zero and two and the scores are added up to provide an immediate assessment of the infant's overall health that is useful in the clinical setting.
- This invention relates to a scoring system that summarizes key factors of atherosclerotic plaque vulnerability into a quantitative number that describes the current status of the lesion and is directly linked to risk of causing clinical events and/or rapid progression of the disease.
- This unique scoring approach accounts for juxtaluminal characteristics of atherosclerotic plaque including the status of the fibrous cap and the presence of any or all main plaque tissue components such as hemorrhage, lipid rich necrotic core, and calcification, as well as inflammatory activity, and their relative distance to the vessel lumen.
- This plaque information is non-invasively acquired in vivo, for example, using magnetic resonance imaging.
- a primary application of the atherosclerotic risk scoring can be found in the clinical diagnosis of human carotid atherosclerosis.
- one or more cross-sectional images of an artery are taken, for example, by magnetic resonance imaging, computed tomography, ultrasonics, positron emission tomography, or the like, including possibly using combinations of one or more of these imaging modalities.
- Components of the plaque such as necrotic core, hemorrhage, and calcification—are identified and located relative to the juxtaluminal region of the artery.
- the image is also analyzed to determine the status and composition of the fibrous cap.
- the fibrous cap may be collagen or mixed tissue (sometimes referred to as “loose matrix”) and may be intact or ruptured.
- An atherosclerotic risk score is then calculated that characterizes the risk associated with the imaged portion of the artery that is dependent on the fibrous cap status and composition and the present of the identified components in the juxtaluminal region of the artery.
- FIG. 1 is a sketch of an exemplary portion of a typical carotid artery
- FIG. 2 is a representative sketch of a magnetic resonance image of a transverse cross-section through section 2 - 2 of the external carotid artery shown in FIG. 1 ;
- FIG. 3 is a flow chart showing the currently preferred method for scoring the risk associated with an atherosclerotic deposit
- FIG. 4 is a table indicating the currently preferred component scoring for the method shown in FIG. 3 ;
- FIG. 5 shows the currently preferred method for combining the component scoring for the method shown in FIG. 3 .
- a thin fibrous cap covering a large, lipid-rich necrotic core appears to be a clear marker of vulnerable plaque.
- the “fibrous cap” is a distinct layer of connective tissue that typically covers the lipid core of a plaque deposit.
- the fibrous cap generally comprises smooth muscle cells in a collagenous-proteoglycan matrix, with varying degrees of infiltration by macrophages and lymphocytes.
- a thinning fibrous cap indicates weakened structural integrity and possible future rupture that may lead to an embolic event.
- MRI carotid magnetic resonance imaging
- fibrous cap rupture juxtaluminal hemorrhage (thrombus)
- juxtaluminal calcification was significantly higher in symptomatic plaque deposits as compared to asymptomatic deposits.
- ruptured fibrous cap, calcium nodules, and endothelial erosions were highly correlated with sudden cardiac death.
- the present invention is directed in part to a method for combining assessments of plaque composition with quantitative or qualitative evaluation of the juxtaluminal characteristics to produce a new, clinically useful, lesion scoring system. It is contemplated that the new scoring system may be adjusted to be specific to the particular artery of interest—for example, the carotid arteries, coronary arteries, and aorta. However, the important aspect is that the scoring system of the present invention utilizes the variables that are important to identifying “vulnerable plaques,” assigns relative weights based on proximity to the vessel lumen, and combines the variables to produce a simple score that reflects or characterizes the risk that the identified plaque will cause thrombo-embolic events, as well as indicating the likely clinical course of the deposit.
- the method for scoring a patient's atherosclerosis is based on an analysis of an image or set of images of a cross-section of the artery showing an atherosclerotic deposit.
- the image or set of images must have sufficient resolution and discrimination to identify the components of the plaque deposit and their location relative to the vessel lumen.
- the cross-sectional image(s) is substantially transverse to the axial direction of the vessel or artery, although it is contemplated that the method may be utilized with cross-sectional images that are parallel to the vessel or at a skewed angle with respect to the vessel axis.
- the cross-sectional image is taken at one or more selected axial positions, substantially perpendicular to the axis of the vessel.
- High-resolution MRI as a noninvasive imaging tool, has proven to be an imaging modality with excellent capability for discriminating tissues of the carotid plaque, including the status and composition of the fibrous cap, and the location of lipid-rich necrotic core, calcification, and hemorrhage within the deposit.
- MRI is currently superior to other imaging modalities in distinguishing soft tissue contrast and has been demonstrated as a useful tool in identifying morphological and compositional features of atherosclerotic plaque both in vitro and in vivo. For example, by using multiple contrast weightings available in MRI, complex plaque tissue components have been accurately characterized and identified. MRI has also been shown to be capable of identifying the fibrous cap in atherosclerotic carotid arteries in vivo.
- high resolution in vivo carotid plaque imaging with a spatial resolution of 0.5 ⁇ 0.5 ⁇ 2 mm 3 has been obtained using a phased-array carotid coil in a 1.5T whole body scanner.
- Soft plaques containing necrotic cores and/or interplaque hemorrhage have been identified with high sensitivity and specificity, the lumen and outer wall boundaries identified, and the fibrous cap and its thickness visualized with gradient echo based time-of-flight imaging.
- CT computed tomography
- PET positron emission tomography
- Any imaging technology or combinations of technologies, that provide sufficient resolution and discrimination to identify and locate the compositions of the plaque deposit in vivo and to evaluate the fibrous cap is suitable for practicing the present invention.
- FIG. 1 shows a sketch of a portion of a carotid artery 100 showing the bifurcation of the common carotid artery 102 into the internal carotid artery 104 and the external carotid artery 106 .
- FIG. 2 shows a sketch of an exemplary MRI image taken through a cross-section of the external carotid artery 106 at section 2 - 2 of FIG. 1 . It should be appreciated that the sketch of FIG. 2 is a simplified depiction of a high-resolution MRI image, presented here to facilitate understanding of the present invention. In practice, a clinician or other healthcare professional may examine more than one image to identify specific features of the atherosclerotic deposit.
- a skilled clinician can identify in the MRI image(s) the artery 106 , outer wall 110 , the atherosclerotic plaque 115 therein, and other components of the plaque 115 , as discussed below.
- image analysis software may be used to identify or facilitate identification of these components.
- the atherosclerotic plaque 115 is substantial.
- a lumen 112 provides a flow path for the blood and a relatively narrow fibrous cap 114 forms the interface between the lumen 112 blood flow and the rest of the plaque deposit 115 .
- the fibrous cap 114 may be ruptured, as indicated at 113 , which may appear in the MRI image as a light or a dark area on the fibrous cap 114 .
- the plaque 115 may include one or more regions of calcification 116 (two shown), one or more necrotic core region(s) 118 and/or hemorrhage(s) 119 .
- the status of the fibrous cap 114 can also be determined from the high-resolution MRI image(s) as either ruptured or intact and the fibrous cap component can be determined as collagen or mixed tissue.
- the location of early or recent hemorrhage 119 , necrotic core 118 , and calcification 116 can also be identified from the MRI image(s)—in particular, the radial position with respect to the lumen 112 , to determine if these components are partially or wholly within the juxtaluminal portion of the plaque deposit 115 .
- the juxtaluminal portion of the plaque deposit 115 comprises the inner one third of the thickness of the plaque 115 , as approximately indicated by the dotted line 120 . It is contemplated, however, that other definitions of the juxtaluminal region may be used without departing from the present invention and that the portion of the plaque 115 that is included in the juxtaluminal portion may depend, for example, on the particular artery of interest (e.g., carotid, aortic, etc.). For example, in some instances it may be preferable to define a larger or smaller portion of the plaque 115 as juxtaluminal or a prescribed thickness of the plaque 115 may be characterized as juxtaluminal. It is also contemplated that different definitions of juxtaluminal may be appropriate for the different components.
- FIG. 3 shows a flow chart of the currently preferred method for scoring the atherosclerotic risk associated with a plaque deposit.
- the clinician(s) first obtains one or more images of cross-sections of an artery of interest 202 —for example, using MRI, ultrasonics, CT, PET, and/or other imaging modality.
- the image(s) is then analyzed and, if a plaque deposit is present, the fibrous cap is identified 204 , its status (intact or ruptured) is determined 206 , and its thickness and/or composition (collagen or mixed tissue) is determined 208 .
- the image(s) is further analyzed to identify and locate any necrotic core 210 , calcification 212 , and hemorrhage 214 . Values are assigned to the features 216 described above—for example, according to the table shown in FIG. 4 —and an atherosclerosis risk scoring is calculated 218 , for example, as indicated in FIG. 5 .
- FIG. 4 presents a table 220 showing the current component scoring system for the features described above 222 , a corresponding variable 224 , and the condition for assigning a value or scoring each variable 226 . If the fibrous cap is intact, FCS is assigned a value of 1; if it is ruptured, then FCS is assigned a value of 2. If the fibrous cap is collagen, FCC is assigned a value of 1; if it is mixed tissue, then FCC is assigned a value of 2. Similarly, if no necrotic core, hemorrhage, and/or calcification is apparent in the image—NC, HE, and CA, respectively—are assigned values of zero.
- the respective variable is assigned a value of 1. If any of these components is found in the juxtaluminal region of the plaque deposit, the respective variable is assigned a value of 2. It will be appreciated that this simple scoring system can be accomplished very quickly and easily from examining the MRI image(s) or by automated image analysis software, as is known in the art.
- the table 230 shows the preferred method for combining the assigned values to generate an atherosclerosis risk score (“ARS”).
- the ARS characterizes the level of risk associated with a patient's atherosclerosis as indicated by a particular cross section of an artery.
- an intermediate value of A is calculated by weighting and adding the scores for the plaque components HE, NC, and CA (hemorrhage, necrotic core, and calcification, respectively).
- NC is multiplied by 0.75
- CA is multiplied by 0.5 before summing these values.
- the fibrous cap status is then accounted for by multiplying the intermediate value A by FCS to produce a second intermediate value B.
- the ARS is determined by accounting for the fibrous cap composition.
- the intermediate value B is multiplied by the value: (1+0.5 ⁇ [FCC ⁇ 1]).
- FIG. 2 shows a ruptured fibrous cap, a juxtaluminal hemorrhage, deep necrotic core, and calcification.
- the histology and MRI data were obtained from 34 patients who were scheduled for a carotid endarterectomy.
- a 1.5T MR scanner was used to obtain pre-contrast images (TOF, T1, PD, and T2 weighted) and post-contrast T1WI MRI (6-10 minutes after contrast administration). Two hundred and sixty locations matched between MRI and excised histology specimens were selected. Cohen's Kappa and Pearson correlation was used to determine agreement and association between MRI and histology results.
- the matched MR images and histology slices showed moderate to good agreement for FC status, FC composition, hemorrhage, necrotic core, and calcification, with the following respective Cohen's Kappa values—0.84, 0.82, 0.73, 0.76, and 0.77, respectively.
- the Pearson Correlation values for Scores A, B, and ARS were 0.84, 0.86, and 0.87, respectively.
- Interclass correlation coefficient values for Scores A, B, and C were 0.84, 0.87, and 0.87, respectively.
- the resulting ARS provides a quick, straightforward, and clinically useful characterization of the risk associated with an atherosclerotic deposit in a patient's artery, wherein higher ARS indicate a greater risk that the atherosclerosis will precipitate a clinical event (e.g., stroke or heart attack) in the near term.
- a clinical event e.g., stroke or heart attack
- juxtaluminal region may be utilized to improve the risk scoring and/or to better match data for arteries other than the carotid artery.
- a set depth such as one millimeter, may be alternatively utilized.
- the details of weighting and combining the scores for FCC, FCS, NC, HE, and CA may be modified without departing from the present invention—for example, to more closely correlate the calculated ARS with clinical outcomes.
- the particular values used in the ARS may be modified, for example, to normalize the ARS to a desired range.
- the above-described scores were assigned for NC, HE and CA (see, FIG. 4 ), but the fibrous cap was scored only for its status, with FCS assigned a value of zero indicating no fibrous cap, a value of one indicating an intact fibrous cap, and a value of two indicating a ruptured fibrous cap.
- the calculated ARS is 10.
- the ARS would be used in conjunction with other clinical information including patient history, habits, and the like.
- a modified ARS may be calculated that further incorporates such information.
Abstract
Description
- The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grant No. RO1HL56874 awarded by the National Institutes of Health.
- The present invention relates generally to methods for assessing a patient's risk associated with atherosclerosis and, more particularly, to clinically efficient methods for characterizing such risks.
- Cardiovascular disease secondary to atherosclerosis is the leading cause of mortality and morbidity worldwide. Growing evidence suggests that the decisive factor determining increased risk for atherosclerotic plaque to cause clinical events is plaque composition rather than the degree of luminal narrowing as measured by angiography.
- Atherosclerosis is a form of arteriosclerosis that is characterized by the deposition of plaques containing cholesterol and lipids on the innermost layer of the walls of arteries. Atherosclerosis is currently understood to be a chronic inflammatory disease rather than an inevitable degenerative aging process. The condition usually affects large- and medium-sized arteries. Although such plaque deposits can significantly reduce the blood's flow through an artery, the more serious risk is generally associated with the instigation of an acute clinical event through plaque rupture and thrombosis. In particular, serious damage can occur if an arterial plaque deposit becomes fragile and ruptures, fissures, or ulcerates. Plaque rupture, fissure, or ulcer can cause blood clots to form that block or occlude blood flow and/or break off and travel to other parts of the body. If such blood clots block a blood vessel that feeds the heart, it causes a heart attack. If the blood clot blocks a blood vessel that feeds the brain, it causes a stroke. Similarly, if blood supply to the arms or legs is reduced, it can cause difficulty in walking or light exercise and other collateral damage. Recent studies indicate that thrombotic complications of atherosclerosis remain the leading cause of morbidity and mortality in Western society.
- Atherosclerosis may start in childhood and may progress at varying rates as a person ages. In some people, atherosclerosis progresses rapidly, even at a relatively young age. Tobacco smoke greatly worsens atherosclerosis and speeds its growth in the coronary arteries, the aorta, and arteries in the legs. Although some factors that correlate with a higher risk of atherosclerosis are not controllable, such as gender and family history, other correlated risk factors are controllable—including, for example, high blood cholesterol levels, exposure to tobacco smoke, high blood pressure, obesity, and physical inactivity.
- The presence and extent of plaque build up in an individual's arteries can be detected using a variety of techniques that are well known in the field including, for example, magnetic resonance imaging (“MRI”), computed tomography (“CT”), X-ray angiography, and ultrasound. Prior art methods for assessing an individual's risk of a clinically significant event such as a stroke or heart attack related to atherosclerotic deposits in an individual's arteries have primarily been directed to evaluating the effect that the plaque deposit has on the blood flow through the artery.
- The risk associated with rupture, fissure, or ulceration of plaque, however, may be present even when the plaque deposit does not significantly reduce the flow of blood in an artery. For example, arteries and other blood vessels will sometimes expand or “remodel” in the region of a significant atherosclerotic plaque deposit such that the lumen area does not decrease sufficiently to significantly reduce blood flow. If the plaque ruptures, it may nevertheless create a blood clot that may travel to a critical area to cause a clinical event. The susceptibility of a plaque deposit to structural failure is difficult to determine.
- In a clinical context it is often useful to evaluate a particular patient or condition using a simplified scoring system that takes into account a large amount of data and a number of different factors in a simplified manner to rapidly characterize the patient's risk. Such methods can provide a rapid means for evaluating a patient's condition and the urgency of providing appropriate treatments. A well known example of such a scoring system is the Apgar scale ubiquitously used to rapidly judge the health of a new born baby wherein, at one minute and again at five minutes after birth, the infant is evaluated for heart rate, respiration, muscle tone, reflex response, and skin color. Each factor is given a score between zero and two and the scores are added up to provide an immediate assessment of the infant's overall health that is useful in the clinical setting.
- With regard to assessing the risk associated with atherosclerosis after imaging a section of a patient's artery having a significant plaque deposit, in the past a medical professional might take hours reviewing the images identifying structures over the region of interest. Such evaluations are clearly not suitable in a clinical setting wherein a rapid evaluation is required.
- Therefore, there remains a need for a relatively simple method and system for assessing the risk associated with an atherosclerotic plaque deposit in a patient's artery.
- This invention relates to a scoring system that summarizes key factors of atherosclerotic plaque vulnerability into a quantitative number that describes the current status of the lesion and is directly linked to risk of causing clinical events and/or rapid progression of the disease. This unique scoring approach accounts for juxtaluminal characteristics of atherosclerotic plaque including the status of the fibrous cap and the presence of any or all main plaque tissue components such as hemorrhage, lipid rich necrotic core, and calcification, as well as inflammatory activity, and their relative distance to the vessel lumen. This plaque information is non-invasively acquired in vivo, for example, using magnetic resonance imaging. A primary application of the atherosclerotic risk scoring can be found in the clinical diagnosis of human carotid atherosclerosis.
- In an embodiment of the invention, one or more cross-sectional images of an artery are taken, for example, by magnetic resonance imaging, computed tomography, ultrasonics, positron emission tomography, or the like, including possibly using combinations of one or more of these imaging modalities. Components of the plaque—such as necrotic core, hemorrhage, and calcification—are identified and located relative to the juxtaluminal region of the artery. The image is also analyzed to determine the status and composition of the fibrous cap. For example, the fibrous cap may be collagen or mixed tissue (sometimes referred to as “loose matrix”) and may be intact or ruptured. An atherosclerotic risk score is then calculated that characterizes the risk associated with the imaged portion of the artery that is dependent on the fibrous cap status and composition and the present of the identified components in the juxtaluminal region of the artery.
- The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:
-
FIG. 1 is a sketch of an exemplary portion of a typical carotid artery; -
FIG. 2 is a representative sketch of a magnetic resonance image of a transverse cross-section through section 2-2 of the external carotid artery shown inFIG. 1 ; -
FIG. 3 is a flow chart showing the currently preferred method for scoring the risk associated with an atherosclerotic deposit; -
FIG. 4 is a table indicating the currently preferred component scoring for the method shown inFIG. 3 ; and -
FIG. 5 shows the currently preferred method for combining the component scoring for the method shown inFIG. 3 . - Histological studies in various vascular beds have established that plaque tissue composition and distribution may strongly influence its clinical course and the likelihood that an atherosclerotic deposit will precipitate a clinical event. For example, a thin fibrous cap covering a large, lipid-rich necrotic core appears to be a clear marker of vulnerable plaque. The “fibrous cap” is a distinct layer of connective tissue that typically covers the lipid core of a plaque deposit. The fibrous cap generally comprises smooth muscle cells in a collagenous-proteoglycan matrix, with varying degrees of infiltration by macrophages and lymphocytes.
- A thinning fibrous cap indicates weakened structural integrity and possible future rupture that may lead to an embolic event. In a study of patients using carotid magnetic resonance imaging (“MRI”) to image a portion of the carotid artery prior to undergoing a carotid endarterectomy, the prevalence of fibrous cap rupture, juxtaluminal hemorrhage (thrombus) and juxtaluminal calcification was significantly higher in symptomatic plaque deposits as compared to asymptomatic deposits. Furthermore, in a landmark study based on coronary autopsy specimens, ruptured fibrous cap, calcium nodules, and endothelial erosions were highly correlated with sudden cardiac death. (Virmani et al., Lessons From Sudden Coronary Death: A Comprehensive Morphological Classification Scheme for Atherosclerotic Lesions, Arterioscler. Thromb. Vasc. Biol. 20:1262-1275, 2000.) These features all involve the interface between the plaque and the lumen or the plaque region immediately adjacent to the lumen (the “juxtaluminal region”). Thus, this juxtaluminal region is crucial to improved identification and understanding of vulnerable plaques.
- The present invention is directed in part to a method for combining assessments of plaque composition with quantitative or qualitative evaluation of the juxtaluminal characteristics to produce a new, clinically useful, lesion scoring system. It is contemplated that the new scoring system may be adjusted to be specific to the particular artery of interest—for example, the carotid arteries, coronary arteries, and aorta. However, the important aspect is that the scoring system of the present invention utilizes the variables that are important to identifying “vulnerable plaques,” assigns relative weights based on proximity to the vessel lumen, and combines the variables to produce a simple score that reflects or characterizes the risk that the identified plaque will cause thrombo-embolic events, as well as indicating the likely clinical course of the deposit.
- In particular, the method for scoring a patient's atherosclerosis is based on an analysis of an image or set of images of a cross-section of the artery showing an atherosclerotic deposit. The image or set of images must have sufficient resolution and discrimination to identify the components of the plaque deposit and their location relative to the vessel lumen. In the currently preferred embodiment the cross-sectional image(s) is substantially transverse to the axial direction of the vessel or artery, although it is contemplated that the method may be utilized with cross-sectional images that are parallel to the vessel or at a skewed angle with respect to the vessel axis. In the currently preferred exemplary method described herein, the cross-sectional image is taken at one or more selected axial positions, substantially perpendicular to the axis of the vessel.
- High-resolution MRI, as a noninvasive imaging tool, has proven to be an imaging modality with excellent capability for discriminating tissues of the carotid plaque, including the status and composition of the fibrous cap, and the location of lipid-rich necrotic core, calcification, and hemorrhage within the deposit. MRI is currently superior to other imaging modalities in distinguishing soft tissue contrast and has been demonstrated as a useful tool in identifying morphological and compositional features of atherosclerotic plaque both in vitro and in vivo. For example, by using multiple contrast weightings available in MRI, complex plaque tissue components have been accurately characterized and identified. MRI has also been shown to be capable of identifying the fibrous cap in atherosclerotic carotid arteries in vivo. For example, high resolution in vivo carotid plaque imaging with a spatial resolution of 0.5×0.5×2 mm3 has been obtained using a phased-array carotid coil in a 1.5T whole body scanner. Soft plaques containing necrotic cores and/or interplaque hemorrhage have been identified with high sensitivity and specificity, the lumen and outer wall boundaries identified, and the fibrous cap and its thickness visualized with gradient echo based time-of-flight imaging.
- Although the currently preferred method for imaging an artery uses high-resolution MRI, it is contemplated that the present invention may be practiced using other imaging techniques, including for example, computed tomography (“CT”), ultrasonics, positron emission tomography (“PET”), and the like, including combinations of these imaging techniques. Any imaging technology or combinations of technologies, that provide sufficient resolution and discrimination to identify and locate the compositions of the plaque deposit in vivo and to evaluate the fibrous cap is suitable for practicing the present invention.
- Refer now to
FIG. 1 , which shows a sketch of a portion of acarotid artery 100 showing the bifurcation of the commoncarotid artery 102 into the internalcarotid artery 104 and the externalcarotid artery 106.FIG. 2 shows a sketch of an exemplary MRI image taken through a cross-section of the externalcarotid artery 106 at section 2-2 ofFIG. 1 . It should be appreciated that the sketch ofFIG. 2 is a simplified depiction of a high-resolution MRI image, presented here to facilitate understanding of the present invention. In practice, a clinician or other healthcare professional may examine more than one image to identify specific features of the atherosclerotic deposit. For example, a skilled clinician can identify in the MRI image(s) theartery 106,outer wall 110, theatherosclerotic plaque 115 therein, and other components of theplaque 115, as discussed below. Alternatively, image analysis software may be used to identify or facilitate identification of these components. - In the exemplary sketch of
FIG. 2 , theatherosclerotic plaque 115 is substantial. Alumen 112 provides a flow path for the blood and a relatively narrowfibrous cap 114 forms the interface between thelumen 112 blood flow and the rest of theplaque deposit 115. Thefibrous cap 114 may be ruptured, as indicated at 113, which may appear in the MRI image as a light or a dark area on thefibrous cap 114. Theplaque 115 may include one or more regions of calcification 116 (two shown), one or more necrotic core region(s) 118 and/or hemorrhage(s) 119. - The status of the
fibrous cap 114 can also be determined from the high-resolution MRI image(s) as either ruptured or intact and the fibrous cap component can be determined as collagen or mixed tissue. The location of early orrecent hemorrhage 119,necrotic core 118, andcalcification 116 can also be identified from the MRI image(s)—in particular, the radial position with respect to thelumen 112, to determine if these components are partially or wholly within the juxtaluminal portion of theplaque deposit 115. - In the current embodiment of the invention, the juxtaluminal portion of the
plaque deposit 115 comprises the inner one third of the thickness of theplaque 115, as approximately indicated by the dottedline 120. It is contemplated, however, that other definitions of the juxtaluminal region may be used without departing from the present invention and that the portion of theplaque 115 that is included in the juxtaluminal portion may depend, for example, on the particular artery of interest (e.g., carotid, aortic, etc.). For example, in some instances it may be preferable to define a larger or smaller portion of theplaque 115 as juxtaluminal or a prescribed thickness of theplaque 115 may be characterized as juxtaluminal. It is also contemplated that different definitions of juxtaluminal may be appropriate for the different components. - When the presence and location of the various components (e.g.,
calcification 116,necrotic core 118, hemorrhage 119) of theplaque deposit 115 and the status and composition of thefibrous cap 114 are determined, simple values are assigned and combined to characterize the risk associated with an imagedplaque deposit 115. - Refer now to
FIG. 3 , which shows a flow chart of the currently preferred method for scoring the atherosclerotic risk associated with a plaque deposit. Typically, the clinician(s) first obtains one or more images of cross-sections of an artery ofinterest 202—for example, using MRI, ultrasonics, CT, PET, and/or other imaging modality. The image(s) is then analyzed and, if a plaque deposit is present, the fibrous cap is identified 204, its status (intact or ruptured) is determined 206, and its thickness and/or composition (collagen or mixed tissue) is determined 208. The image(s) is further analyzed to identify and locate anynecrotic core 210,calcification 212, andhemorrhage 214. Values are assigned to thefeatures 216 described above—for example, according to the table shown inFIG. 4 —and an atherosclerosis risk scoring is calculated 218, for example, as indicated inFIG. 5 . -
FIG. 4 presents a table 220 showing the current component scoring system for the features described above 222, a corresponding variable 224, and the condition for assigning a value or scoring each variable 226. If the fibrous cap is intact, FCS is assigned a value of 1; if it is ruptured, then FCS is assigned a value of 2. If the fibrous cap is collagen, FCC is assigned a value of 1; if it is mixed tissue, then FCC is assigned a value of 2. Similarly, if no necrotic core, hemorrhage, and/or calcification is apparent in the image—NC, HE, and CA, respectively—are assigned values of zero. If any of these components are found in the image but in a deep portion of the plaque (i.e., not in the juxtaluminal region), then the respective variable is assigned a value of 1. If any of these components is found in the juxtaluminal region of the plaque deposit, the respective variable is assigned a value of 2. It will be appreciated that this simple scoring system can be accomplished very quickly and easily from examining the MRI image(s) or by automated image analysis software, as is known in the art. - Referring now to
FIG. 5 , the table 230 shows the preferred method for combining the assigned values to generate an atherosclerosis risk score (“ARS”). The ARS characterizes the level of risk associated with a patient's atherosclerosis as indicated by a particular cross section of an artery. In the currently preferred embodiment, an intermediate value of A is calculated by weighting and adding the scores for the plaque components HE, NC, and CA (hemorrhage, necrotic core, and calcification, respectively). In particular, NC is multiplied by 0.75 and CA is multiplied by 0.5 before summing these values. The fibrous cap status is then accounted for by multiplying the intermediate value A by FCS to produce a second intermediate value B. Finally, the ARS is determined by accounting for the fibrous cap composition. In particular, the intermediate value B is multiplied by the value: (1+0.5×[FCC−1]). Obviously, the particulars of this calculation are broken up to better elucidate the present invention and to highlight the impact that the various components contribute to the final ARS. The details of the particular weightings and the specific combination of the values should also be clear to the artisan that alternative scoring systems may be used without departing from the teaching of the present invention. - As an example, refer to
FIG. 2 , which shows a ruptured fibrous cap, a juxtaluminal hemorrhage, deep necrotic core, and calcification. Assume the fibrous cap is determined to be collagen so that FCC=1; FCS=2; HE=2; NC=1 and CA=1. Then A is 3.25, B is 6.50 and the ARS is 6.5. - To validate this scoring system, the histology and MRI data were obtained from 34 patients who were scheduled for a carotid endarterectomy. A 1.5T MR scanner was used to obtain pre-contrast images (TOF, T1, PD, and T2 weighted) and post-contrast T1WI MRI (6-10 minutes after contrast administration). Two hundred and sixty locations matched between MRI and excised histology specimens were selected. Cohen's Kappa and Pearson correlation was used to determine agreement and association between MRI and histology results. The matched MR images and histology slices showed moderate to good agreement for FC status, FC composition, hemorrhage, necrotic core, and calcification, with the following respective Cohen's Kappa values—0.84, 0.82, 0.73, 0.76, and 0.77, respectively. The Pearson Correlation values for Scores A, B, and ARS were 0.84, 0.86, and 0.87, respectively. Interclass correlation coefficient values for Scores A, B, and C were 0.84, 0.87, and 0.87, respectively. These strong correlations indicate that MRI-based atherosclerosis scoring is able to provide similar information as histology.
- The resulting ARS provides a quick, straightforward, and clinically useful characterization of the risk associated with an atherosclerotic deposit in a patient's artery, wherein higher ARS indicate a greater risk that the atherosclerosis will precipitate a clinical event (e.g., stroke or heart attack) in the near term.
- While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention. It is contemplated, for example, that alternative methods of defining the juxtaluminal region may be utilized to improve the risk scoring and/or to better match data for arteries other than the carotid artery. For example, a set depth, such as one millimeter, may be alternatively utilized. It is also contemplated that the details of weighting and combining the scores for FCC, FCS, NC, HE, and CA may be modified without departing from the present invention—for example, to more closely correlate the calculated ARS with clinical outcomes. Obviously the particular values used in the ARS may be modified, for example, to normalize the ARS to a desired range.
- In another simplified embodiment of the invention, for example, the above-described scores were assigned for NC, HE and CA (see,
FIG. 4 ), but the fibrous cap was scored only for its status, with FCS assigned a value of zero indicating no fibrous cap, a value of one indicating an intact fibrous cap, and a value of two indicating a ruptured fibrous cap. The ARS was then simply calculated by weighting FCS and HE by two, and summing the values, i.e. ARS=2×FCS+2×HE+NC+CA. Again referring toFIG. 2 wherein FCS=2; HE=2; NC=1 and CA=1. In this simplified alternative embodiment the calculated ARS is 10. - It is also contemplated that the ARS would be used in conjunction with other clinical information including patient history, habits, and the like. For example, a modified ARS may be calculated that further incorporates such information.
Claims (18)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/172,415 US7340083B2 (en) | 2005-06-29 | 2005-06-29 | Method and system for atherosclerosis risk scoring |
PCT/US2006/025346 WO2007002821A2 (en) | 2005-06-29 | 2006-06-28 | Method and system for atherosclerosis risk scoring |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/172,415 US7340083B2 (en) | 2005-06-29 | 2005-06-29 | Method and system for atherosclerosis risk scoring |
Publications (2)
Publication Number | Publication Date |
---|---|
US20070003116A1 true US20070003116A1 (en) | 2007-01-04 |
US7340083B2 US7340083B2 (en) | 2008-03-04 |
Family
ID=37589581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/172,415 Expired - Fee Related US7340083B2 (en) | 2005-06-29 | 2005-06-29 | Method and system for atherosclerosis risk scoring |
Country Status (2)
Country | Link |
---|---|
US (1) | US7340083B2 (en) |
WO (1) | WO2007002821A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090270731A1 (en) * | 2008-04-24 | 2009-10-29 | Boston Scientific Scimed, Inc | Methods, systems, and devices for tissue characterization by spectral similarity of intravascular ultrasound signals |
WO2010008565A2 (en) * | 2008-07-16 | 2010-01-21 | Cardiac Pacemakers, Inc. | Systems for treatment of atherosclerosis and infarction |
US20100016913A1 (en) * | 2008-07-16 | 2010-01-21 | Shantha Arcot-Krishnamurthy | Intermittent pacing therapy for angina and disease prevention |
US20100137711A1 (en) * | 2008-11-25 | 2010-06-03 | Trustees Of Boston University | Apparatus and Method of Analyzing Arterial Plaque |
US8313437B1 (en) | 2010-06-07 | 2012-11-20 | Suri Jasjit S | Vascular ultrasound intima-media thickness (IMT) measurement system |
US20130053698A1 (en) * | 2011-08-29 | 2013-02-28 | Infraredx, Inc. | Detection of lipid core plaque cap thickness |
US8485975B2 (en) | 2010-06-07 | 2013-07-16 | Atheropoint Llc | Multi-resolution edge flow approach to vascular ultrasound for intima-media thickness (IMT) measurement |
US8532360B2 (en) | 2010-04-20 | 2013-09-10 | Atheropoint Llc | Imaging based symptomatic classification using a combination of trace transform, fuzzy technique and multitude of features |
US8639008B2 (en) | 2010-04-20 | 2014-01-28 | Athero Point, LLC | Mobile architecture using cloud for data mining application |
US8708914B2 (en) | 2010-06-07 | 2014-04-29 | Atheropoint, LLC | Validation embedded segmentation method for vascular ultrasound images |
US8805043B1 (en) | 2010-04-02 | 2014-08-12 | Jasjit S. Suri | System and method for creating and using intelligent databases for assisting in intima-media thickness (IMT) |
US9549713B2 (en) | 2008-04-24 | 2017-01-24 | Boston Scientific Scimed, Inc. | Methods, systems, and devices for tissue characterization and quantification using intravascular ultrasound signals |
US10456105B2 (en) | 2015-05-05 | 2019-10-29 | Boston Scientific Scimed, Inc. | Systems and methods with a swellable material disposed over a transducer of an ultrasound imaging system |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090204338A1 (en) * | 2008-02-13 | 2009-08-13 | Nordic Bioscience A/S | Method of deriving a quantitative measure of the instability of calcific deposits of a blood vessel |
US20100017182A1 (en) * | 2008-07-15 | 2010-01-21 | Szilard Voros | Method for coronary artery disease risk assessment |
US20100312090A1 (en) * | 2009-06-05 | 2010-12-09 | University of Washington Center for Commercialization | Atherosclerosis risk assessment by projected volumes and areas of plaque components |
US20110245650A1 (en) * | 2010-04-02 | 2011-10-06 | Kerwin William S | Method and System for Plaque Lesion Characterization |
US8867822B2 (en) | 2011-10-14 | 2014-10-21 | Fujifilm Corporation | Model-based coronary artery calcium scoring |
CN114134029A (en) | 2012-02-13 | 2022-03-04 | 纽莫德克斯莫勒库拉尔公司 | Microfluidic cartridge for processing and detecting nucleic acids |
US11485968B2 (en) | 2012-02-13 | 2022-11-01 | Neumodx Molecular, Inc. | Microfluidic cartridge for processing and detecting nucleic acids |
US10776654B2 (en) | 2015-03-10 | 2020-09-15 | Infraredx, Inc. | Assessment of lipid core plaque integrity |
CN114340496A (en) * | 2019-10-29 | 2022-04-12 | 未艾医疗技术(深圳)有限公司 | Analysis method and related device of heart coronary artery based on VRDS AI medical image |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030215124A1 (en) * | 2002-05-20 | 2003-11-20 | Jianying Li | Method and apparatus of scoring an arterial obstruction |
US20040022359A1 (en) * | 2002-07-31 | 2004-02-05 | Kishore Acharya | Method, system and computer product for plaque characterization |
US20040133100A1 (en) * | 2002-08-23 | 2004-07-08 | Morteza Naghavi | Novel risk assessment method based upon coronary calcification distribution pattern imaged by computed tomography |
US6763261B2 (en) * | 1995-09-20 | 2004-07-13 | Board Of Regents, The University Of Texas System | Method and apparatus for detecting vulnerable atherosclerotic plaque |
US6816743B2 (en) * | 1998-10-08 | 2004-11-09 | University Of Kentucky Research Foundation | Methods and apparatus for in vivo identification and characterization of vulnerable atherosclerotic plaques |
US7149331B1 (en) * | 2002-09-03 | 2006-12-12 | Cedara Software Corp. | Methods and software for improving thresholding of coronary calcium scoring |
-
2005
- 2005-06-29 US US11/172,415 patent/US7340083B2/en not_active Expired - Fee Related
-
2006
- 2006-06-28 WO PCT/US2006/025346 patent/WO2007002821A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6763261B2 (en) * | 1995-09-20 | 2004-07-13 | Board Of Regents, The University Of Texas System | Method and apparatus for detecting vulnerable atherosclerotic plaque |
US6816743B2 (en) * | 1998-10-08 | 2004-11-09 | University Of Kentucky Research Foundation | Methods and apparatus for in vivo identification and characterization of vulnerable atherosclerotic plaques |
US20030215124A1 (en) * | 2002-05-20 | 2003-11-20 | Jianying Li | Method and apparatus of scoring an arterial obstruction |
US20040022359A1 (en) * | 2002-07-31 | 2004-02-05 | Kishore Acharya | Method, system and computer product for plaque characterization |
US20040133100A1 (en) * | 2002-08-23 | 2004-07-08 | Morteza Naghavi | Novel risk assessment method based upon coronary calcification distribution pattern imaged by computed tomography |
US7149331B1 (en) * | 2002-09-03 | 2006-12-12 | Cedara Software Corp. | Methods and software for improving thresholding of coronary calcium scoring |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9549713B2 (en) | 2008-04-24 | 2017-01-24 | Boston Scientific Scimed, Inc. | Methods, systems, and devices for tissue characterization and quantification using intravascular ultrasound signals |
US20090270731A1 (en) * | 2008-04-24 | 2009-10-29 | Boston Scientific Scimed, Inc | Methods, systems, and devices for tissue characterization by spectral similarity of intravascular ultrasound signals |
WO2010008565A2 (en) * | 2008-07-16 | 2010-01-21 | Cardiac Pacemakers, Inc. | Systems for treatment of atherosclerosis and infarction |
US20100016913A1 (en) * | 2008-07-16 | 2010-01-21 | Shantha Arcot-Krishnamurthy | Intermittent pacing therapy for angina and disease prevention |
US20100016916A1 (en) * | 2008-07-16 | 2010-01-21 | Shantha Arcot-Krishnamurthy | Apparatus and methods for treatment of atherosclerosis and infarction |
WO2010008565A3 (en) * | 2008-07-16 | 2010-05-06 | Cardiac Pacemakers, Inc. | Systems for treatment of atherosclerosis and infarction |
US20100137711A1 (en) * | 2008-11-25 | 2010-06-03 | Trustees Of Boston University | Apparatus and Method of Analyzing Arterial Plaque |
WO2010068486A1 (en) * | 2008-11-25 | 2010-06-17 | Trustees Of Boston University | Apparatus and method of analyzing arterial plaque |
US8805043B1 (en) | 2010-04-02 | 2014-08-12 | Jasjit S. Suri | System and method for creating and using intelligent databases for assisting in intima-media thickness (IMT) |
US8639008B2 (en) | 2010-04-20 | 2014-01-28 | Athero Point, LLC | Mobile architecture using cloud for data mining application |
US8532360B2 (en) | 2010-04-20 | 2013-09-10 | Atheropoint Llc | Imaging based symptomatic classification using a combination of trace transform, fuzzy technique and multitude of features |
US8708914B2 (en) | 2010-06-07 | 2014-04-29 | Atheropoint, LLC | Validation embedded segmentation method for vascular ultrasound images |
US8485975B2 (en) | 2010-06-07 | 2013-07-16 | Atheropoint Llc | Multi-resolution edge flow approach to vascular ultrasound for intima-media thickness (IMT) measurement |
US8313437B1 (en) | 2010-06-07 | 2012-11-20 | Suri Jasjit S | Vascular ultrasound intima-media thickness (IMT) measurement system |
US20130053698A1 (en) * | 2011-08-29 | 2013-02-28 | Infraredx, Inc. | Detection of lipid core plaque cap thickness |
US8958867B2 (en) * | 2011-08-29 | 2015-02-17 | Infraredx, Inc. | Detection of lipid core plaque cap thickness |
US20150150461A1 (en) * | 2011-08-29 | 2015-06-04 | Infraredx, Inc. | Detection of Lipid Core Plaque Cap Thickness |
US9918643B2 (en) * | 2011-08-29 | 2018-03-20 | Infraredx, Inc. | Detection of lipid core plaque cap thickness |
US10456105B2 (en) | 2015-05-05 | 2019-10-29 | Boston Scientific Scimed, Inc. | Systems and methods with a swellable material disposed over a transducer of an ultrasound imaging system |
Also Published As
Publication number | Publication date |
---|---|
WO2007002821A3 (en) | 2008-08-14 |
US7340083B2 (en) | 2008-03-04 |
WO2007002821A2 (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7340083B2 (en) | Method and system for atherosclerosis risk scoring | |
Ravaioli et al. | Noninvasive assessment of portal hypertension in advanced chronic liver disease: an update | |
Li et al. | Does calcium deposition play a role in the stability of atheroma? Location may be the key | |
Saam et al. | The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment | |
Randoux et al. | Carotid artery stenosis: prospective comparison of CT, three-dimensional gadolinium-enhanced MR, and conventional angiography | |
Nasu et al. | Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology | |
Harloff et al. | 3D blood flow characteristics in the carotid artery bifurcation assessed by flow‐sensitive 4D MRI at 3T | |
Bannas et al. | Longitudinal monitoring of hepatic blood flow before and after TIPS by using 4D-flow MR imaging | |
Bogaert et al. | Coronary artery imaging with real-time navigator three-dimensional turbo-field-echo MR coronary angiography: initial experience | |
JP2007502676A (en) | Automated method and system for vascular plaque detection and analysis | |
US20100137711A1 (en) | Apparatus and Method of Analyzing Arterial Plaque | |
EP3005943B1 (en) | Novel magnetic resonance image technique for imaging and evaluating collateral circulation | |
JP5730879B2 (en) | Device and system for determining the likelihood of a patient having a clinical or clinical asymptomatic event based on identified physiological parameters | |
Chiu et al. | Characterization of carotid plaques on 3‐dimensional ultrasound imaging by registration with multicontrast magnetic resonance imaging | |
Lindenholz et al. | Intracranial atherosclerosis assessed with 7-T MRI: evaluation of patients with ischemic stroke or transient ischemic attack | |
Matsumoto et al. | Contemporary diagnostic approaches to acute pulmonary emboli | |
Schoenhagen et al. | Coronary artery calcification and end-stage renal disease: vascular biology and clinical implications | |
Chu et al. | Cardiac magnetic resonance features of the disruption-prone and the disrupted carotid plaque | |
Arnoldussen et al. | Clinical impact of assessing thrombus age using magnetic resonance venography prior to catheter-directed thrombolysis | |
US20090088624A1 (en) | Methods and Apparatus for Diagnosing and Treating Aneurysms | |
Elefteriades | Acute aortic disease | |
Worthley et al. | Coronary artery imaging in the new millennium | |
Saleh et al. | Complex adult congenital heart disease on cross-sectional imaging: an introductory overview | |
JP4751337B2 (en) | A method for computer-aided visualization of diagnostic image data | |
Xiao et al. | Computed tomography angiography assessment of the degree of simple coarctation of the aorta and its relationship with surgical outcome: A retrospective analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CV PATH, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VIRMANI, RENU;REEL/FRAME:016479/0576 Effective date: 20050822 Owner name: UNIVERSITY OF WASHINGTON, WASHINGTON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YUAN, CHUN;HATSUKAMI, THOMAS S.;CAI, JIANMING;AND OTHERS;REEL/FRAME:016471/0469;SIGNING DATES FROM 20050725 TO 20050824 |
|
AS | Assignment |
Owner name: CVPATH INSTITUTE, INC., MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VIRMANI, RENU;REEL/FRAME:017845/0281 Effective date: 20060622 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Expired due to failure to pay maintenance fee |
Effective date: 20200304 |